AAIC 2017: Electronic Self-Administered Test Performs Similarly to Pen-and-Paper Version in Detecting MCI and Early Dementias

Monday, July 17, 2017 | Dementia & Cognitive Disorders


Findings presented at the Alzheimer’s Association International Conference in London indicate that the self-administered eSAGE (BrainTest Inc.) test performs similar to its validated pen-and-paper counterpart (SAGE) in detecting mild cognitive impairment and early dementias. Led by Douglas W. Scharre, MD, Professor of Clinical Neurology and Psychiatry at The Ohio State University Wexner Medical Center, investigators randomly selected individuals aged 50 and over who had taken SAGE to participate in a clinical evaluation including neuropsychological evaluations over an 18-month period. SAGE and eSAGE were administered using a crossover design. They found that eSAGE performs similarly with neuropsychological batteries, MoCA, and MMSE and shows no scale bias compared to the paper test. eSAGE had a high sensitivity (71 percent) and specificity (90 percent) in detecting cognitive impairment from normal participants. The results of the study were recently published in Alzheimer’s Research & Therapy.

To learn more about eSAGE, read Practical Neurology®’s Q&A with Dr. Scharre from the January/February 2017 edition

Next Story

Comments

You must be logged in to leave a comment.